Character Biosciences Secures $93M for Clinical Trials Targeting Dry AMD

Character Biosciences has raised $93 million in a Series B funding round to advance clinical trials for two programs aimed at treating dry age-related macular degeneration (AMD). The biotech company plans to focus on geographic atrophy, an advanced stage of the disease. This funding will support testing of therapies designed to address different stages of the condition, which currently has limited treatment options.

The announcement follows recent FDA approvals for geographic atrophy treatments from Apellis Pharmaceuticals and Astellas Pharma. Character Biosciences claims its approach could offer a competitive alternative in this space. The company aims to develop what it describes as “best-in-class” therapies, though specific details about its drug candidates or trial timelines have not been disclosed.

Date: March, 2025

Newsflash | Powered by GeneOnline AI

Author

Mark Chiang